Navigation Links
Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial

-therapy with ACP-103 also provided a significantly faster onset of antipsychotic action. After only two weeks of therapy, about 50% more patients in the ACP-103/risperidone arm responded to treatment compared to each of the risperidone LD (p less than 0.008) and risperidone HD (p less than 0.03) arms. A responder was defined as a patient showing at least a 20% reduction in the PANSS.

Importantly, patients in the ACP-103/risperidone co-therapy arm also had 50% less gain in weight than patients in the risperidone HD arm. This difference trended to statistical significance (p=0.078).

The study also evaluated ACP-103 as a co-therapy with haloperidol. The ACP-103/haloperidol arm showed a 21.6 point (25.6%) improvement in the PANSS as measured after day 42 compared to baseline (p less than 0.0001), a primary endpoint in the study. The haloperidol arm showed a robust antipsychotic effect and there was no statistical difference compared to the ACP-103/haloperidol arm after day 42. However, the ACP-103/haloperidol arm did appear to result in a faster onset of antipsychotic action after only two weeks of treatment as compared to the haloperidol arm. In addition, patients in the ACP-103/haloperidol co-therapy arm had less gain in weight compared to patients in the haloperidol arm. -0-

Study Arms                                  Baseline Mean   Percentage
Mean     Change  Change
----------------------------------------------------------------------
ACP-103 (20 mg) plus haloperidol (2 mg)     85.6     -21.6  25.6%
----------------------------------------------------------------------
Haloperidol (2 mg) plus placebo             86.4     -25.1  29.2%
----------------------------------------------------------------------
Data based on the PANSS using the Intent to Treat Population and Last
Observation Carried Forward Methodology.

Each of the treatments was generally safe and well tolerated. Adverse events were comparable among the five study arms
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

Post Your Comments:
(Date:11/25/2009)... CHAPELHILL,N.C.,Nov.25/PRNewswire/--CempraPharmac...,presidentandchiefexecutiveofficer,willpresentatth....m.EST,December1,2009,atTheNewYorkPalaceHotelinNew...pany,stwoleadingantibioticclinicalprogramsforthetr..., AboutCempraPharmaceuticals ,, Foundedin200...
(Date:11/25/2009)... NEWYORK,Nov.25/PRNewswire/--Reportlinker.comannou...talogue: ,, IntranasalDrugDelivery-USMarketTre...4267/Intranasal-Drug-Delivery---US-Market-Trends--...rketiswitnessinganexpansionoftherapeuticapplicatio...gstothedeliveryofsystemictherapeuticdrugs.Thefutur...
(Date:11/25/2009)... FRAMINGHAM,Mass.andSYDNEY,Nov.25/PRNewswire-First...SX:HIN),aleadinginnovatorandprovideroflessinvasive...ionizingthetreatmentofadvancedheartfailure,todayan...onatthe21stAnnualPiperJaffrayHealthCareConferencea...isbeingheldattheNewYorkPalaceHotel,December1-2. ,...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID 28R 29 Molecular Cancer Classifier in United Kingdom Ireland 58927 1bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID 28R 29 Molecular Cancer Classifier in United Kingdom Ireland 58927 2bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID 28R 29 Molecular Cancer Classifier in United Kingdom Ireland 58927 3R Tech Ueno Starts Early Phase II Clinical Trial for RK 023 5244 1R Tech Ueno Starts Early Phase II Clinical Trial for RK 023 5244 2R Tech Ueno Starts Early Phase II Clinical Trial for RK 023 5244 3People with Disabilities Face Unique Healthcare Coverage Challenges Allsup Says 58921 1People with Disabilities Face Unique Healthcare Coverage Challenges Allsup Says 58921 2People with Disabilities Face Unique Healthcare Coverage Challenges Allsup Says 58921 3People with Disabilities Face Unique Healthcare Coverage Challenges Allsup Says 58921 4People with Disabilities Face Unique Healthcare Coverage Challenges Allsup Says 58921 5People with Disabilities Face Unique Healthcare Coverage Challenges Allsup Says 58921 6
... in Advanced Cancer Patients, ROCKVILLE, Md., Apr...nical-stage pharmaceutical company developing,ther...ory diseases, today,announced that it has commence...ith its oral cell cycle inhibitor, MKC-1, in patie...clinical trial will be conducted at the,University...
... funding CoAxia,s studies of its NeuroFlo(TM) ...Stroke, MINNEAPOLIS, April 1, 2008 CoAxia(TM), I...g of an additional $11.5M financing,from current i...ngoing,clinical trials. The investment is an exten...allow CoAxia to continue its SENTIS pivotal FDA tr...
Other Medicine Technology:EntreMed Commences Continuous Dosing Clinical Trial For MKC-1 2EntreMed Commences Continuous Dosing Clinical Trial For MKC-1 3EntreMed Commences Continuous Dosing Clinical Trial For MKC-1 4CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors 2
(Date:11/26/2009)...rom the North Pole, Textsanta.net lets parents sig... North Pole, AK (PRWEB) -- ...at the North Pole Santa Claus has added SMS text m...informed of his Christmas progress at the North Po... have identified a large and growing percentage of...
(Date:11/26/2009)...ions announces a highly effective and unconvention... to make an economic recovery. , ...the type of challenge that could send ailing holid...avid Benton, business growth expert and author of ... The Rfactor Intensive . “Fear is one of t...
(Date:11/25/2009)...TheBartleHallConventionCenterwilltemporarilybecome...asCityhoststhelatestinaseriesofmassivefreeclinicsf...epotentialtobethebiggestoneyet,becauseitwillextend...eadofoveraweekend,"SheriWood,executivedirectorofth...alAssociationofFreeClinics(NAFC). ,, Atprevious...
(Date:11/25/2009)...leMedicalInc.,aleadingmanufacturerofbreastMRIcoils...wleadingedgeclinicalapplicationsonitsAegis(TM)medi...SocietyofNorthAmerica(RSNA)annualmeetinginChicago,...leveragetheuniquehighqualityimagesgeneratedbySenti...eimagingmodalitiesformulti-parametricassessment. ,...
(Date:11/25/2009)...wire/--TheBlackAIDSInstituterecentlyheldBoardofDir...0. ,, ThenewBoardMembersareahighlydiversegroupo...governmenthealthprograms,editorial,andbusinessentr...onalbackgroundsincludingbothheterosexualandgayBlac...entingmultipleagegroups. ,, (Photo: http://www....
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2
...n this week’s Australian Medical Journal (AMA) has...aesarean face a greater risk of complications if t...nancies. // The study has found wome...rectomies than women who go through natural labour...
...d Forskolin has been found to be helpful in inhibi...ML) cells in cultures and mice by up to 90 percent...plant coleus forskohlii, a native of India that is... mistakenly exchanging genetic material in chromos...
... organisms, are exposed to ever-changing environme...cs.// Bacteria are able to defend themselves again...iotics and attain new abilities simply by ‘stealin...cording to the new research, published in the curr...
...hemistry and Industry magazine says that tropical ...osquitoes that transmit malaria, dengue and other ...has been implicated in about 23 diseases and this ...mboo in a greenhouse leading to fears that they mi...
...f human resources, has been hospitalized after he ...ived in this twin capital of Punjab and Haryana Su...stitute of Medical Education and Research (PGIMER)...ttend the inauguration of the regional office of t...
...kinds of live mutated viruses can cure tumors in a...from the University of Glasgow treated a patient w...ding the method safe in animals, the New Scientist...er he is still alive and his tumor has gone, the ...
Other Medicine News:Health News:Chronic Myelogenous Leukemia (CML) Has An Answer Now! 2Health News:Chronic Myelogenous Leukemia (CML) Has An Answer Now! 3Health News:Bacteria Evolve Armamentarium Against Antibiotics By ‘Stealing’ Gen 2
...tretch Vascular Grafts have met the challenges of ... for exceptional performance and quality, they hav...dwide. These grafts require no preclotting, resist...e utmost thrombectomy safety. The GORE-TEX Stretch...
...olving techniques for vascular surgery, and the ac...that new, specialized types of graft be developed....atible, but also available in varying sizes and co...X Vascular Graft has long been the prosthetic of c...
...ascular Grafts have met the challenges of the most...Recognized for exceptional performance and quality...geons worldwide. These grafts require no preclotti... and assure utmost thrombectomy safety. The Gore v...
...eg; Vascular Grafts have met the challenges of the...ars. Recognized for exceptional performance and qu...d surgeons worldwide. These grafts require no prec...tion, and assure utmost thrombectomy safety. Gore ...
Medicine Products: